Equity Profile

CRL

Charles River Laboratories International, Inc.

Health CareLife Sciences Tools & Services$11.1B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Charles River Laboratories International, Inc. (CRL) operates in the health care sector, focusing on life sciences tools and services....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and is closely watched by investors.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its business and capture market share in the life sciences sector.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CRL Q2-2026 Earnings Preview

Context

Company Snapshot

Charles River Laboratories International, Inc. (CRL) operates in the health care sector, focusing on life sciences tools and services. The company plays a crucial role in supporting the pharmaceutical and biotechnology industries by providing essential services for drug development and research.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+10.31%

Avg Stock Reaction

+1.27%

Last Quarter Recap

In Q1-2026, Charles River Laboratories reported an EPS of $2.06, beating expectations by 5.21%. However, the stock experienced a slight decline of 0.03% the following day.

Management Promises & Guidance

Continued focus on expanding service offerings in drug development.
Commitment to improving operational efficiency.
Plans to enhance customer engagement and satisfaction.

Expectations

Wall Street Expectations

Overall, expectations for Charles River Laboratories are mixed, with investors looking for signs of continued growth and profitability. The company's historical performance shows a strong track record of beating earnings estimates.

Bull Case

If CRL continues its trend of beating EPS estimates and shows strong revenue growth, it could lead to a positive market reaction and increased investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a negative reaction from investors, especially given the current market volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's strong history of beating EPS estimates, this number will be crucial in determining market sentiment.

How is the company addressing operational efficiency?

Investors will be looking for specific strategies to improve margins and profitability, especially in a competitive market.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for CRL to exceed EPS expectations due to its strong historical performance and operational improvements.

Supporting Evidence

CRL has consistently beaten EPS estimates in the past, with a 100% beat rate over the last eight quarters.

Options pricing suggests a significant move, indicating that the market is bracing for volatility.

The company's commitment to enhancing operational efficiency may lead to better-than-expected margins.

Key Risk

If the EPS comes in below $1.90, it could undermine the positive sentiment surrounding the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is currently weighing the company's ability to maintain its growth trajectory against potential operational challenges.

Bull Confirmed If

An EPS of $2.10 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $1.90 would signal potential issues with profitability and growth.

Pre-Earnings Positioning

Options Market

Implied Move

±10.01%

Historical Avg

±8.5%

Pricing rich

The options market is pricing in a significant move of about 10% in either direction, indicating uncertainty about the upcoming earnings report.

Options are pricing ±10.0% while CRL has averaged ±8.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

60.1%

Calls (154K)P/C Ratio: 1.46Puts (22K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRL beats expectations, history suggests the stock could rise by about 1.27% on the first day, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further commentary from management.

Miss

A miss could lead to a decline, with historical patterns indicating an average drop of around 8.50% following disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on operational efficiency initiatives.
2Details on revenue growth in key segments.
3Management's outlook on market conditions and competitive landscape.
4Insights into customer engagement strategies.
5Any commentary on future service offerings and innovations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Charles River Laboratories International, Inc. (CRL) operates in the health care sector, focusing on life sciences tools and services....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and is closely watched by investors.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its business and capture market share in the life sciences sector.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CRL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+10.31%

Avg Stock Reaction

+1.27%

Last Quarter Recap

In Q1-2026, Charles River Laboratories reported an EPS of $2.06, beating expectations by 5.21%. However, the stock experienced a slight decline of 0.03% the following day.

Management Promises & Guidance

Continued focus on expanding service offerings in drug development.
Commitment to improving operational efficiency.
Plans to enhance customer engagement and satisfaction.

Expectations

Wall Street Expectations

Bull Case

If CRL continues its trend of beating EPS estimates and shows strong revenue growth, it could lead to a positive market reaction and increased investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a negative reaction from investors, especially given the current market volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's strong history of beating EPS estimates, this number will be crucial in determining market sentiment.

How is the company addressing operational efficiency?

Investors will be looking for specific strategies to improve margins and profitability, especially in a competitive market.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for CRL to exceed EPS expectations due to its strong historical performance and operational improvements.

Supporting Evidence

CRL has consistently beaten EPS estimates in the past, with a 100% beat rate over the last eight quarters.

Options pricing suggests a significant move, indicating that the market is bracing for volatility.

The company's commitment to enhancing operational efficiency may lead to better-than-expected margins.

Key Risk

If the EPS comes in below $1.90, it could undermine the positive sentiment surrounding the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is currently weighing the company's ability to maintain its growth trajectory against potential operational challenges.

Bull Confirmed If

An EPS of $2.10 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $1.90 would signal potential issues with profitability and growth.

Pre-Earnings Positioning

Options Market

Implied Move

±10.01%

Historical Avg

±8.5%

Pricing rich

The options market is pricing in a significant move of about 10% in either direction, indicating uncertainty about the upcoming earnings report.

Options are pricing ±10.0% while CRL has averaged ±8.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

60.1%

Calls (154K)P/C Ratio: 1.46Puts (22K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRL beats expectations, history suggests the stock could rise by about 1.27% on the first day, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further commentary from management.

Miss

A miss could lead to a decline, with historical patterns indicating an average drop of around 8.50% following disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on operational efficiency initiatives.
2Details on revenue growth in key segments.
3Management's outlook on market conditions and competitive landscape.
4Insights into customer engagement strategies.
5Any commentary on future service offerings and innovations.